The GLP-1 industry is currently an oligopoly ruled by two pharmaceutical giants, Novo Nordisk A/S (NYSE: NVO), maker of semaglutide under the Ozempic and Wegovy name brands, and Eli Lilly & Co. (NYSE: LLY), maker of tirzepatide and dual GLP-1/GIP agonist treatment sold under Mounjaro and Zepbound name brands. As compounding facilities cease making compounded versions of their drugs, which are no longer on the FDA drug shortage list, the medical sector oligopoly will likely regain many more users to seal their dominance.
However, there are many contenders in the works. One of the most promising GLP-1 contenders is VK2735, a dual GLP-1/GIP receptor agonist similar to tirzepatide, owned by Viking Therapeutics Inc. (NASDAQ: VKTX).
